Mounjaro vs Zepbound: Should You Switch? The Evidence

Mounjaro and Zepbound are the same molecule — tirzepatide, made by Eli Lilly — in the same six dose strengths from the same plant. The difference is the box on the label. Mounjaro is FDA-approved for type 2 diabetes (May 2022). Zepbound is FDA-approved for chronic weight management (November 2023) and obstructive sleep apnea in obese adults (December 2024). Insurance keys off the label, not the molecule, which is why switching between the two brands is less about pharmacology and more about which indication your plan will pay for. This article walks the labels, the dose-equivalence math (there is none — the doses are literally identical), and the practical switching protocol for the four most common patient scenarios.

The honest summary

• Same active ingredient, same doses, same pens. Mounjaro and Zepbound are both tirzepatide 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg in a 0.5 mL pre-filled single-dose pen. Lilly also sells Zepbound single-dose vials direct-to-consumer through LillyDirect. The molecule, the manufacturing site, and the pharmacokinetics are identical.
• FDA labels are different. Mounjaro is approved for type 2 diabetes only (Mounjaro label^[7]). Zepbound is approved for chronic weight management (FDA Nov 2023^[5]) and for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA Dec 2024^[6]). A MASH (NASH) indication has not yet been added — the phase 3 SYNERGY-NASH readout is pending; the phase 2 result from Loomba 2024 NEJM^[4] is what the field is working from.
• Insurance follows the label. Commercial insurance typically covers Mounjaro for documented T2D and covers Zepbound for obesity only when the employer has bought the obesity rider. Medicare Part D covers Mounjaro for T2D and (since 2025) Zepbound for OSA in obese adults^[10]; neither program covers either brand for obesity alone under standard Part D rules.
• Cash pay is now a real third option. LillyDirect sells Zepbound single-dose vials at roughly $349 / $499 / $599 per month for the 2.5 / 5 / 7.5 mg doses^[9] — about a third of the retail pen price and within range of compounded tirzepatide. There is no equivalent Mounjaro cash-pay vial channel.

What the labels actually say

Mounjaro (tirzepatide; FDA approval May 13, 2022) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (Mounjaro DailyMed label^[7]). The label does not include weight management, does not include cardiovascular risk reduction (the SURPASS-CVOT cardiovascular outcomes trial has not yet reported as of 2026-05-29), and does not include OSA or MASH. Mounjaro is what a prescriber writes when the diagnosis is T2D.

Zepbound (tirzepatide; FDA approval November 8, 2023 for obesity, December 20, 2024 for OSA) carries two indications on its current label (Zepbound DailyMed label^[8]): chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, and moderate-to-severe obstructive sleep apnea in adults with obesity. The OSA indication is what drove Medicare Part D to add Zepbound coverage in 2025^[10]; it was the first time Medicare covered an obesity-class medication under any clinical pathway.

The pivotal evidence is consistent across the program. SURMOUNT-1 (Jastreboff 2022 NEJM^[1]) showed −20.9% total body weight at 72 weeks on tirzepatide 15 mg vs −3.1% on placebo. SURPASS-2 (Frias 2021 NEJM^[2]) compared tirzepatide head-to-head with semaglutide 1 mg in T2D and showed superior HbA1c reduction across all three tirzepatide doses. SURMOUNT-OSA (Malhotra 2024 NEJM^[3]) showed −25 to −30 events per hour on the apnea-hypopnea index. SYNERGY-NASH phase 2 (Loomba 2024 NEJM^[4]) showed roughly 44–62% MASH resolution without fibrosis worsening across the three doses.

Dose equivalence: there isn't any — the doses are identical

Both products ship in the same six pen strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg in a 0.5 mL pre-filled single-dose injector. Switching from Mounjaro 7.5 mg to Zepbound 7.5 mg is a brand swap, not a dose adjustment. Pharmacokinetics, half-life, dose-titration schedule (start 2.5 mg weekly, escalate every four weeks), injection sites (abdomen, thigh, upper arm), and storage rules (refrigerate 36–46°F; up to 21 days at room temperature) are identical between brands. A prescriber writing for Zepbound 7.5 mg in a patient previously stable on Mounjaro 7.5 mg should not adjust the dose at the swap, and should not re-titrate from 2.5 mg unless there has been a gap of more than four weeks off therapy.

Lilly launched single-dose Zepbound vials in the second half of 2024 and expanded the LillyDirect cash-pay channel through 2025 and 2026^[9]. Vials require the patient to draw with a separate insulin syringe rather than dial a pen, but the drug, dose, and clinical effect are the same as the pen. There is no Mounjaro vial.

Insurance reality: what your plan will actually pay

Commercial insurance coverage is the single biggest driver of which brand a patient ends up on, and it is much less symmetrical than the label parity suggests.

• Commercial plans (employer-sponsored): roughly 70–80% of plans cover Mounjaro for documented T2D, usually with a prior authorization that requires HbA1c ≥ 6.5% or documented metformin failure. Zepbound coverage for obesity runs roughly 30–45% and depends on whether the employer has bought the obesity-medication rider. Zepbound for OSA is now covered by a growing share of commercial plans as the FDA indication has worked its way into pharmacy benefit formularies.
• Medicare Part D: Mounjaro is covered for T2D across most plans. Zepbound was not covered by Medicare until the OSA indication was added in 2024; since 2025, Medicare Part D covers Zepbound for moderate-to-severe OSA in adults with obesity^[10]. Obesity alone is still excluded under the Medicare Modernization Act statutory carve-out.
• Medicaid: coverage is state-by-state. Most state Medicaid programs cover Mounjaro for T2D with prior authorization. As of early 2026, roughly a dozen state Medicaid programs cover Zepbound for obesity in adults; more cover it for OSA in obese adults. Always check the current state formulary.

The Lilly Savings Card for Mounjaro caps commercially-insured patient cost at roughly $25 per month for a 1-, 2-, or 3-month fill, and offers up to $573 off for uninsured cash-pay patients (subject to monthly limits). The Zepbound Savings Card works similarly on the pen side. On the vial side, LillyDirect sells directly to cash-pay patients without an insurance loop.

Cost magnitude: annual out-of-pocket by pathway

The four switching scenarios

Almost every Mounjaro-vs-Zepbound conversation lands in one of four buckets.

1. You have T2D and commercial coverage for Mounjaro. Stay on Mounjaro. T2D coverage is the most widely-honored tirzepatide indication; there is no clinical reason to switch to Zepbound, and most commercial plans will not pay for Zepbound when a T2D diagnosis is on file. If you develop obesity-only comorbidities, your Mounjaro stays the same medication.
2. You are on Zepbound for obesity and your plan drops coverage. Three options. First, check whether a T2D or OSA diagnosis applies — if so, switch to Mounjaro for T2D or document OSA to preserve Zepbound coverage. Second, apply for LillyDirect cash-pay vials at $349–$599 per month^[9]. Third, ask your prescriber about appealing the coverage drop with a letter of medical necessity citing SURMOUNT-1^[1] and SURMOUNT-OSA^[3].
3. You were on compounded tirzepatide and need to switch to branded. The fastest cash-pay route is Zepbound vials via LillyDirect at the dose you were taking (or the next dose down). The vials use the same draw-from-vial workflow as the compounded product so the technique transfers; the molecule and dose are the same. See our current FDA status for compounded tirzepatide for the regulatory backdrop on why this transition is now the default path for most patients.
4. You are between insurance plans and need a bridge. Skipping doses for more than four weeks usually requires restarting at 2.5 mg, which is clinically wasteful. A LillyDirect Zepbound vial fill for one or two months at the patient's current dose preserves the titration and avoids the GI side-effect re-introduction that comes with a restart.

Practical operational notes

• Prescriptions are brand-specific. A Mounjaro script does not fill as Zepbound at the pharmacy and vice versa. The pharmacist cannot brand-swap; the prescriber must re-issue.
• Prior authorization runs on diagnosis. The PA form asks for the ICD-10 code — E11.x for T2D (Mounjaro pathway), E66.x for obesity or G47.33 for OSA (Zepbound pathway). Selecting the wrong code or omitting a comorbidity is the most common reason a PA gets denied.
• Refill timing matters. If you switch brands mid-month, you may end up paying out of pocket for the remaining days of the previous fill. Time the swap to a natural refill boundary.
• Storage and waste rules are the same. Both pens (and Zepbound vials) ship cold; both tolerate up to 21 days at room temperature; both are single-use; sharps disposal is identical.

Related research

• Can You Still Get Compounded Tirzepatide in 2026? — the §503A and §503B wind-down and which patients can still legally fill a compounded script
• Compounded tirzepatide vs Zepbound bioequivalence evidence — why FDA never required a bioequivalence study and what the published in-process data does and does not say
• Compounded vs branded GLP-1 patient decision guide — the cost, supply, and regulatory math across both tirzepatide and semaglutide
• SURMOUNT-OSA tirzepatide sleep apnea evidence — the Malhotra 2024 NEJM data behind Zepbound's OSA indication and how it changes Medicare coverage

Important disclaimer. This article is educational and does not constitute medical advice. Brand-switch decisions and prior-authorization paperwork should be made with a prescribing clinician and a pharmacist who can verify the current formulary status of your plan. Insurance coverage, Lilly Savings Card terms, and LillyDirect vial pricing change periodically; the figures in this article were verified on 2026-05-29 against Lilly's public materials and the published FDA labels. PMIDs were verified live against the PubMed E-utilities API on the same date.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if Mounjaro adds a new indication (CV risk reduction expected from SURPASS-CVOT) or Zepbound adds a MASH indication after SYNERGY-NASH phase 3 readout.